Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ALB | P02768 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | TK1 | P04183 | 5/20 | 0.38 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
| ▸ | TYMP | P19971 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4263186 | 1.00 | ALDH1A1 (0.39) | ALDH1A1LMNAALBPOLBADRA1A | |
| SCHEMBL4261514 | 1.00 | ALDH1A1 (0.39) | ALDH1A1LMNAALBPOLBADRA1A | |
| SCHEMBL4269958 | 1.00 | ALDH1A1 (0.39) | ALDH1A1LMNAALBPOLBADRA1A | |
| SCHEMBL4259801 | 1.00 | ALDH1A1 (0.39) | ALDH1A1LMNAALBPOLBADRA1A | |
| SCHEMBL4275804 | 0.89 | RNASE1 (0.45) | ALDH1A1LMNAALBPOLBADRA1A | |
| SCHEMBL4267257 | 0.89 | RNASE1 (0.45) | ALDH1A1LMNAALBPOLBADRA1A | |
| SCHEMBL4261563 | 0.89 | RNASE1 (0.45) | ALDH1A1LMNAALBPOLBADRA1A | |
| SCHEMBL4261262 | 0.89 | RNASE1 (0.45) | ALDH1A1LMNAALBPOLBADRA1A | |
| SCHEMBL4268441 | 0.89 | RNASE1 (0.45) | ALDH1A1LMNAALBPOLBADRA1A | |
| SCHEMBL4264583 | 0.84 | ALDH1A1 (0.40) | ALDH1A1LMNAALBPOLBADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8227431-B2 | Nucleoside derivatives | HETERO DRUGS LIMITED (IN) | 2012-07-24 | — | — | US | claimed |
| WO-2009115893-A2 | NOVEL NUCLEOSIDE DERIVATIVES | HETERO RESEARCH FOUNDATION (IN) | 2009-09-24 | — | — | WO | claimed |
| US-20090233879-A1 | NOVEL NUCLEOSIDE DERIVATIVES | HETERO DRUGS LIMITED (IN) | 2009-09-17 | — | — | US | claimed |
| US-8227431-B2 | Nucleoside derivatives | HETERO DRUGS LIMITED (IN) | 2012-07-24 | — | — | US | disclosed |
| WO-2009115893-A2 | NOVEL NUCLEOSIDE DERIVATIVES | HETERO RESEARCH FOUNDATION (IN) | 2009-09-24 | — | — | WO | disclosed |
| US-20090233879-A1 | NOVEL NUCLEOSIDE DERIVATIVES | HETERO DRUGS LIMITED (IN) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233879-A1 | NOVEL NUCLEOSIDE DERIVATIVES | ENTPD5, PNP, ENTPD1 | ALDH1A1 2855/4885LMNA 2060/4885ALB 4828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.